BTIG Research Issues Positive Forecast for Carlsmed (NASDAQ:CARL) Stock Price

Carlsmed (NASDAQ:CARL) had its price objective increased by BTIG Research from $23.00 to $24.00 in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also commented on CARL. Truist Financial boosted their target price on shares of Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings raised shares of Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Needham & Company LLC started coverage on shares of Carlsmed in a report on Wednesday, July 1st. They issued a “buy” rating and a $17.00 price target for the company. Finally, Wall Street Zen upgraded shares of Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.50.

Carlsmed Stock Up 2.5%

CARL opened at $14.78 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.84 and a quick ratio of 8.66. Carlsmed has a 12 month low of $8.50 and a 12 month high of $17.23. The stock has a market capitalization of $403.54 million, a P/E ratio of -10.34 and a beta of 2.09. The business has a 50 day simple moving average of $14.97 and a 200-day simple moving average of $12.28.

Carlsmed (NASDAQ:CARL) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The firm had revenue of $18.94 million for the quarter. Carlsmed had a negative return on equity of 38.06% and a negative net margin of 57.42%. On average, equities analysts anticipate that Carlsmed will post -1.50 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Carlsmed

A number of institutional investors and hedge funds have recently modified their holdings of the company. Zevenbergen Capital Investments LLC increased its stake in Carlsmed by 50.4% in the 3rd quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock valued at $252,000 after purchasing an additional 6,000 shares in the last quarter. Bank of America Corp DE acquired a new position in Carlsmed during the second quarter worth $108,000. Jupiter Topco LLC purchased a new stake in Carlsmed during the second quarter worth $12,992,000. Parkman Healthcare Partners LLC purchased a new stake in Carlsmed during the second quarter worth $6,200,000. Finally, Alpine Woods Capital Investors LLC acquired a new stake in Carlsmed in the second quarter valued at $161,000.

Carlsmed Company Profile

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company develops patient-specific implants and digital planning tools intended to help surgeons address spinal deformity and degenerative conditions with procedures tailored to an individual patient’s anatomy and surgical goals.

Its principal products are offered under the aprevo brand and include personalized interbody fusion implants produced using three-dimensional printing, along with software that supports implant design and preoperative planning.